Pharmafile Logo

postmenopausal osteoporosis

- PMLiVE

UCB partners with Daiichi to bring epilepsy drug to Japan

Companies partner on expanding market for Vimpat

- PMLiVE

Amgen/AZ confirm brodalumab psoriasis filing in 2015

Drug demonstrates greater effectiveness than J&J’s Stelara

- PMLiVE

Deaths cause Amgen to drop stomach cancer drug

Increase in patient mortality in patients taking rilotumumab during trial

- PMLiVE

Amgen and AZ’s psoriasis antibody beats Stelara in study

Brodalumab cleared all skin lesions in 37% compared to Stelara’s 18.5%

- PMLiVE

FDA to review Amgen’s cholesterol drug

US regulator accepts first in new class of PCSK9 inhibitors

- PMLiVE

UCB to sell its US generics business for $1.5bn

Advent International and Avista Capital Partners will take control of Kremers Urban Pharmaceuticals

- PMLiVE

Amgen’s trebananib misses survival target in ovarian cancer

First phase III trial improved survival rates by just one month

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen should split up, says investor

Hedge fund manager Daniel Loeb criticises big biotech firm's 'bloated cost structure'

- PMLiVE

Amgen appoints R Sanders Williams to board of directors

He is president of Gladstone Institutes

- PMLiVE

Amgen files lawsuit to block PCSK9 rivals

Firm suing Sanofi and Regeneron for patent infringement

- PMLiVE

Amgen leukaemia drug gets FDA priority review

Adds to breakthrough status for blinatumomab

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links